Protein Summary
Catalyzes the cyclization of (S)-2,3 oxidosqualene to lanosterol, a reaction that forms the sterol nucleus. Through the production of lanosterol may regulate lens protein aggregation and increase transparency. The protein encoded by this gene catalyzes the conversion of (S)-2,3 oxidosqualene to lanosterol. The encoded protein is a member of the terpene cyclase/mutase family and catalyzes the first step in the biosynthesis of cholesterol, steroid hormones, and vitamin D. Alternative splicing results in multiple transcript variants encoding different isoforms.[provided by RefSeq, Feb 2009]
- ENST00000356396
- ENSP00000348762
- ENSG00000160285
- ENST00000397728
- ENSP00000380837
- ENST00000457828
- ENSP00000409191
- ENST00000522411
- ENSP00000429133
- OSC
- OSC
- HYPT14
- CTRCT44
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
disease perturbation | 0.83 | ||
small molecule perturbation | 0.8 | ||
transcription factor perturbation | 0.8 | ||
histone modification site profile | 0.76 | ||
gene perturbation | 0.72 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 1152.57 (req: < 5)
Gene RIFs: 9 (req: <= 3)
Antibodies: 146 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 1152.57 (req: >= 5)
Gene RIFs: 9 (req: > 3)
Antibodies: 146 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 5
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligands: 94
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0